Compare Adaptive Biotechnologies Corp (ADPT) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs D Wave Quantum Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.99 (market cap $4.04B), while D Wave Quantum Inc trades at $20.63 (market cap $7.53B). The key difference: D Wave Quantum Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | QBTS | |
|---|---|---|
Market Cap | $4.04B | $7.53B |
Sector | Health | Technology |
52-Week High | $25.45 | $44.78 |
52-Week Low | $12.30 | $12.98 |
Enterprise Value | $4.10B | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
D-Wave Quantum (QBTS) trades at $20.57, up 1.86% on the day, with a bearish technical signal despite unanimous analyst buy ratings. The stock exhibits extreme valuation metrics, including a P/S ratio of 583.84, while fundamentals show deep losses with a net income margin of -2001.59% in 2026. Recent Q2 2026 earnings missed revenue estimates but highlighted a 1120% surge in bookings, per Barrons on August 6, 2026.
The outlook hinges on commercial adoption of quantum computing, offering speculative upside with a consensus price target of $38.29, but high execution risks and cash burn pose significant threats to shareholder value amid volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
